M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes

Recruiting

Conditions: Hereditary Colorectal Cancer Syndrome

Interventions: Behavioral: Questionnaires
Procedure: Blood Draw/Saliva Sample

First Posted Date: 2016-08-11

Last Posted Date: 2025-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2000

Registration Number: NCT02863172

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Young-Onset Colorectal Cancer

Active, not recruiting

Conditions: Colorectal Carcinoma
Colon Adenocarcinoma
Rectal Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Other: Medical Chart Review
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-08-11

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 818

Registration Number: NCT02863107

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson League City, League City, Texas, United States
🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States

and more 2 locations

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Phase 2

Active, not recruiting

Conditions: Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent High Risk Myelodysplastic Syndrome
Recurrent Hodgkin Lymphoma
Recurrent Non-Hodgkin Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Acute Lymphoblastic Leukemia
High Risk Myelodysplastic Syndrome
Recurrent Plasma Cell Myeloma
High Risk Acute Myeloid Leukemia
Lymphoproliferative Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Other: Pharmacological Study
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2016-08-10

Last Posted Date: 2025-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 204

Registration Number: NCT02861417

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Phase 2

Recruiting

Conditions: Refractory Transformed Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Transformed Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Richter Syndrome

Interventions: Drug: Atezolizumab
Other: Laboratory Biomarker Analysis
Biological: Obinutuzumab
Drug: Venetoclax

First Posted Date: 2016-07-27

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT02846623

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial

Not Applicable

Active, not recruiting

Conditions: Colorectal Cancer Prevention

Interventions: Other: Regular Diet
Other: Navy Beans (Canned)

First Posted Date: 2016-07-25

Last Posted Date: 2025-04-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 71

Registration Number: NCT02843425

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Phase 1

Withdrawn

Conditions: Leukemia
FLT3-Mutated High-Risk Myelodysplastic Syndrome
FLT3-Mutated Acute Myeloid Leukemia

Interventions: Drug: Ponatinib
Drug: 5-azacytidine
Behavioral: Phone Calls

First Posted Date: 2016-07-12

Last Posted Date: 2017-06-02

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02829840

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

Early Phase 1

Completed

Conditions: Human Immunodeficiency Virus
Malignant Neoplasms of Mesothelial and Soft Tissue

Interventions: Behavioral: Screening Interview
Device: Carbon Monoxide Test
Behavioral: Self-Help Materials
Procedure: Visual Oral Screening Examination
Procedure: Direct Fluorescent Oral Visualization Examination
Procedure: Oral Biopsy

First Posted Date: 2016-07-06

Last Posted Date: 2022-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT02823847

Locations: 🇺🇸
Bering Omega/Houston Area Community Services, Houston, Texas, United States

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma and Other Malignant Neoplasms of Skin
Metastatic Melanoma

Interventions: Drug: Azacitidine
Drug: Pembrolizumab

First Posted Date: 2016-06-28

Last Posted Date: 2025-02-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT02816021

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Phase 2

Completed

Conditions: Advanced and/or Metastatic Sarcoma

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2016-06-28

Last Posted Date: 2025-06-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 57

Registration Number: NCT02815995

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Early Phase 1

Active, not recruiting

Conditions: Hydronephrosis
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant
Renal Pelvis Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage II Renal Pelvis Cancer AJCC v7
Stage II Ureter Cancer AJCC v7
Stage II Urethral Cancer AJCC v7

Interventions: Biological: Durvalumab
Procedure: Therapeutic Conventional Surgery
Biological: Tremelimumab

First Posted Date: 2016-06-24

Last Posted Date: 2025-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT02812420

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy